Stacy L ChinFounder, KeepYourEquity · I get the government to write you checks

Where Government Money Flows

30 Jan 2026 · 1 min

Watch on YouTube

0:54

In this opening segment, Stacy Chin frames the 2025 biotech funding environment as a period of severe venture capital contraction—valuations fell and private capital dried up for early‑stage companies. She contrasts this with continued, and even expanding, government investment through NIH, ARPA‑H, and the DOD, which are already planning their 2026 funding streams. Chin positions the upcoming year as a potential “biggest non‑dilutive funding year yet” and promises to outline the three top biotech trends for 2026 and the specific areas where each agency is likely to allocate money, giving founders actionable guidance on how to align their startup strategies to capture this government capital.

Chapters

Here's what most founders don't realize. All right, let's face it. 2025 was a tough year across biotech. Investors are pulling back, valuations shrink, and private capital nearly vanished for many early-stage founders. But here's what most founders don't realize. While venture money froze, the government kept spending in this sector. In fact, NIH, ARPA-H, and DOD are already mapping out what does their 2026 funding flow might look like in order to set the stage for one of the biggest non-diluted funding years yet to come. So if you want to know where the money's headed so that you can align your startup strategy now, stick around to this video and let's dive in because I'm going to walk you through the top 3 biotech trends of 2026, and I'm going to tell you where I think NIH, ARPA-H, and DOD are investing next so that you can best position your startup and innovation to win.